Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TWICE-IRI: Optimized Irinotecan + Aflibercept in mCRC
NCT04392479Phase 3Unknown
- Sponsor
- Hôpital Franco-Britannique - Fondation Cognacq-Jay
- Start
- Sep 2020
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of irinotecan in metastatic colorectal cancer (mCRC), sponsored by Hôpital Franco-Britannique - Fondation Cognacq-Jay. Status: unknown.
02
Drugs
irinotecan
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT04392479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04392479.